New: Evolving the Heatmap: Dow Jones, Nasdaq 100, Russell 2000, and More

Learn More
Last Close
Sep 16  •  04:00PM ET
17.44
Dollar change
-0.01
Percentage change
-0.06
%
IndexRUT P/E- EPS (ttm)-4.63 Insider Own15.50% Shs Outstand14.27M Perf Week-9.40%
Market Cap248.90M Forward P/E- EPS next Y-5.59 Insider Trans-0.51% Shs Float12.06M Perf Month-14.97%
Enterprise Value-14.65M PEG- EPS next Q-1.25 Inst Own95.89% Short Float22.71% Perf Quarter-8.07%
Income-84.39M P/S- EPS this Y-10.27% Inst Trans-15.13% Short Ratio17.15 Perf Half Y3.38%
Sales0.00M P/B0.91 EPS next Y-18.44% ROA-35.38% Short Interest2.74M Perf YTD-23.71%
Book/sh19.15 P/C0.91 EPS next 5Y-15.14% ROE-39.41% 52W High74.49 -76.59% Perf Year-56.79%
Cash/sh19.24 P/FCF- EPS past 3/5Y-57.13% -10.74% ROIC-30.02% 52W Low6.88 153.67% Perf 3Y-20.00%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility8.92% 6.42% Perf 5Y-93.10%
Dividend TTM- EV/Sales- EPS Y/Y TTM-24.84% Oper. Margin- ATR (14)1.34 Perf 10Y-94.45%
Dividend Ex-Date- Quick Ratio18.07 Sales Y/Y TTM-100.00% Profit Margin- RSI (14)36.80 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio18.07 EPS Q/Q4.21% SMA20-9.73% Beta1.60 Target Price47.40
Payout- Debt/Eq0.04 Sales Q/Q-100.00% SMA50-15.49% Rel Volume1.18 Prev Close17.45
Employees107 LT Debt/Eq0.03 EarningsAug 11 AMC SMA200-5.40% Avg Volume159.68K Price17.44
IPOMar 07, 2014 Option/ShortYes / Yes EPS/Sales Surpr.9.47% - Trades Volume188,326 Change-0.06%
Date Action Analyst Rating Change Price Target Change
Jun-17-25Initiated Craig Hallum Buy $50
May-16-25Downgrade Robert W. Baird Outperform → Neutral $24
Jun-27-24Initiated BMO Capital Markets Outperform $65
Jun-11-24Initiated Robert W. Baird Outperform $54
Apr-29-24Initiated Leerink Partners Outperform $46
Mar-21-24Initiated William Blair Outperform $61
Jan-08-24Initiated H.C. Wainwright Buy $45
Jan-05-24Initiated Stifel Buy $31
Jan-04-24Initiated TD Cowen Outperform
Sep-05-25 04:01PM
Aug-20-25 11:02AM
Aug-11-25 05:55PM
04:10PM
Aug-08-25 04:01PM
04:01PM Loading…
Jul-03-25 04:01PM
Jun-30-25 04:01PM
Jun-18-25 09:16AM
Jun-06-25 04:01PM
May-26-25 11:15AM
May-16-25 07:00AM
May-09-25 07:30AM
May-08-25 04:01PM
Apr-28-25 05:00PM
Apr-02-25 04:01PM
11:50AM Loading…
Apr-01-25 11:50AM
Mar-24-25 04:10PM
Feb-24-25 07:30AM
Nov-18-24 05:25PM
04:14PM
09:48AM
06:45AM
Nov-12-24 04:10PM
10:18AM
06:58AM
Nov-11-24 04:01PM
Nov-05-24 07:54AM
Nov-04-24 07:30AM
Oct-21-24 07:30AM
Aug-09-24 02:52PM
07:30AM Loading…
07:30AM
Aug-07-24 07:30AM
Jul-02-24 07:30AM
Jul-01-24 07:30AM
Jun-19-24 09:23AM
Jun-18-24 09:26AM
Jun-05-24 07:30AM
Jun-03-24 07:30AM
May-10-24 01:54PM
07:30AM
May-07-24 06:19AM
Apr-22-24 04:36PM
Mar-20-24 05:31AM
Mar-18-24 04:14PM
Mar-04-24 07:30AM
Feb-29-24 07:30AM
Jan-16-24 07:00AM
Jan-05-24 07:00AM
Dec-19-23 07:00AM
Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company was founded in May 2007 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cobb StuartChief Scientific OfficerMay 14 '25Sale15.156,797103,00320,794May 15 04:43 PM
STUART COBBOfficerMay 14 '25Proposed Sale15.516,797105,421May 14 04:29 PM
Cvijic Christine MikailPresident and CFOMar 13 '25Sale16.944,50176,24772,343Mar 17 05:14 PM
Samsara BioCapital GP, LLC10% OwnerNov 26 '24Buy25.8348,7701,259,6231,717,127Nov 27 04:39 PM
Cvijic Christine MikailPresident and CFONov 22 '24Buy20.4824,000491,40076,844Nov 25 09:29 PM
McMinn RachelChief Executive OfficerNov 22 '24Buy20.4047,500969,0001,297,859Nov 25 09:29 PM